SRDAN VERSTOVSEK to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Randomized Controlled Trials as Topic.
Connection Strength
0.838
-
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023 07 25; 7(14):3582-3591.
Score: 0.122
-
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep; 18(27):2999-3009.
Score: 0.114
-
New Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S69-S71.
Score: 0.100
-
Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs. 2019 06; 24(2):93-105.
Score: 0.091
-
JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 07 13; 130(2):115-125.
Score: 0.080
-
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Apr; 100(4):479-88.
Score: 0.068
-
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res. 2013 Aug; 37(8):911-6.
Score: 0.060
-
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
Score: 0.057
-
JAK2 inhibitors: are they the solution? Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S28-36.
Score: 0.052
-
Phase III MANIFEST-2: pelabresib?+ ruxolitinib vs placebo?+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022 Sep; 18(27):2987-2997.
Score: 0.029
-
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021 Apr; 17(12):1449-1458.
Score: 0.026
-
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 05; 32(5):1057-1069.
Score: 0.021
-
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer. 2016 Apr 15; 122(8):1160-8.
Score: 0.018